Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.07 USD
Change Today +0.83 / 8.11%
Volume 1.4M
ADXS On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

advaxis inc (ADXS) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/8/15 - $30.13
52 Week Low
10/14/14 - $2.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADVAXIS INC (ADXS)

Related News

No related news articles were found.

advaxis inc (ADXS) Related Businessweek News

No Related Businessweek News Found

advaxis inc (ADXS) Details

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

20 Employees
Last Reported Date: 01/6/15
Founded in 2002

advaxis inc (ADXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.

advaxis inc (ADXS) Key Developments

Advaxis, Inc. - Special Call

To discuss further details of the clinical hold

Advaxis, Inc. Announces Phase 1b Dose-Escalation Clinical Study of ADXS-HER2

Advaxis, Inc. announced that the first patient was treated in a Phase 1b dose-escalation clinical study of ADXS-HER2 for the treatment of patients with metastatic HER2 expressing solid tumors. The Phase 1b clinical trial is the first-in-human study of Advaxis's lead Lm Technology immunotherapy product for HER2 expressing cancers. The dose escalation portion of the study will investigate the safety and tolerability of ADXS-HER2 as a monotherapy in approximately 18 patients diagnosed with metastatic HER2 expressing solid tumors, which include breast, gastric, esophageal and osteosarcoma. Once the maximum tolerated dose (MTD) and recommended Phase 2 dose have been identified, up to 80 patients may be enrolled in up to four HER2 expressing tumor specific cohorts in the expansion phase of the study. Advaxis plans to establish the MTD from the Phase 1b study in pediatric patients and work with Children's Oncology Group (COG) to potentially launch a pivotal trial in pediatric osteosarcoma in 2016. This Phase 1b study builds upon efficacy and safety data from Phase 1 clinical studies of ADXS-HER2 conducted in dogs with osteosarcoma, which may have important translational relevance for human patients with osteosarcoma and other HER2 expressing cancers. Preliminary data from a Phase 1 clinical trial in canine osteosarcoma presented at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum suggested ADXS-HER2 safely delayed or prevented the development of metastatic disease and prolonged overall survival in pet dogs with osteosarcoma when administered after amputation and chemotherapy. Results from this trial led to ADXS-HER2 being considered by the U.S. Department of Agriculture (USDA) for expedited approval to treat canine osteosarcoma. Furthermore, preliminary data from a second ongoing canine Phase 1/2 trial presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting suggested that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that are not candidates for primary tumor removal (amputation).

Advaxis, Inc. - Special Call

To review the Stage 1 clinical data from the GOG-0265 study presented at AGOS 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXS:US $11.07 USD +0.83

ADXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Argos Therapeutics Inc $5.80 USD -0.185
Eurocine Vaccines AB kr1.87 SEK +0.08
Genocea Biosciences Inc $5.99 USD -0.18
GenVec Inc $2.02 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ADXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVAXIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at